Literature DB >> 6616466

Combined cytotoxic effect of low-dose 5-fluorouracil and hydroxyurea on 9L cells in vitro.

S Kobayashi, T Hoshino.   

Abstract

Continuous exposure of exponentially growing 9L rat brain tumor cells for 24 hr to a nontoxic dose (0.77 microM) of 5-fluorouracil (5-FUra) produced a progressive increase in S-phase cells from 35% (asynchronous culture) to 70% as shown by DNA histograms based on data obtained by flow cytometry. When 9L cells were treated with the S-phase-specific agent hydroxyurea (1.3 mM) immediately after treatment with 5-FUra, a synergistic cell kill resulted. A centrifugal elutriation study confirmed that enhanced cell kill was caused in part by the S-phase synchrony produced by 5-FUra and to the S-phase specificity of hydroxyurea. A higher dose (7.7 microM) of 5-FUra caused a partial G1-S block; subsequent treatment with hydroxyurea also enhanced cell kill, but the enhancement was not related to S-phase synchrony. A centrifugal elutriation study suggested that, after 24-hr treatment with 5-FUra, hydroxyurea might kill both cells in S phase, which has the greater number of clonogenic cells, and kill cells that are in other phases of the cell cycle, including cells blocked at the G1-S border that are vulnerable to the phenomenon of "thymidineless death"; concomitant administration of thymidine along with 5-FUra eliminated enhanced cell kill.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6616466

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  3 in total

1.  Experimental combination chemotherapy with thymidylate synthetase and ribonucleotide reductase inhibitors.

Authors:  S Kobayashi; T Hoshino; D V Santi
Journal:  Pharm Res       Date:  1984-07       Impact factor: 4.200

2.  Radiation therapy combined with radiosensitizing agents for cerebral glioblastoma in adults.

Authors:  M Matsutani; O Nakamura; M Nakamura; T Nagashima; A Asai; T Fujimaki; H Tanaka; K Ueki; Y Tanaka
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

3.  Phase I trial of high-dose infusional hydroxyurea, high-dose infusional 5-fluorouracil and recombinant interferon-alpha-2a in patients with advanced malignancies.

Authors:  S Wadler; H Haynes; R Schechner; A Rozenblit; P H Wiernik
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.